Functionalized Polymers
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 14/499,354, filed Sep 29, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,125,220 | Functionalized Polymers Grace period ended Nov 13, 2026 · lapse expected · Low confidence | Quiapeg Pharmaceuticals AB | Grace period ended Nov 13, 2026 lapse expected | Low confidence | ||
| US 11,773,219 | Functionalized Polymers In force · High confidence | Quiapeg Pharmaceuticals AB | In force | High confidence | ||
| US 10,781,286 | Functionalized Polymers Lapsed Sep 22, 2024 on the fee record High confidence | Quiapeg Pharmaceuticals AB | Lapsed Sep 22, 2024 on the fee record | High confidence | ||
| US 9,790,324 | Functionalized Polymers Lapsed Oct 17, 2025 on the fee record High confidence | Quiapeg Pharmaceuticals AB | Lapsed Oct 17, 2025 on the fee record | High confidence | ||
| US 8,846,941 | Functionalized Polymers Lapsed Sep 30, 2026 on the fee record High confidence | Quiapeg Pharmaceuticals AB | Lapsed Sep 30, 2026 on the fee record | High confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Quiapeg Pharmaceuticals AB.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.